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The clinical course of squamous cell carcinoma of the head and neck (SCCHN) is determined by both host and tumour factors (Bloom et al, 1984) . Tumour size, degree of differentiation and stage at the time of presentation are important prognostic indicators (Cachin, 1975; Hibbert et al, 1983) . However, it is the presence or absence of lymph node metastasis that is the most important prognostic indicator . Thus the identification of those patients with primary tumours that are likely to develop lymph node metastases is of major importance in the choice of treatment. For metastasis to occur, cells need to detach from their neighbours, migrate through the basement membrane and interstitial matrix, and invade the lymph and blood transport systems (Liotta et al, 1988; Ponta et al, 1994) . Tumour cells exhibit reduced intercellular adhesion compared with normal cells, consistent with the down-regulation, or loss of function, of one of the key adhesion molecules responsible for the maintenance of the orderly structure of differentiated tissue. Changes or alterations in the function and expression of the cell-cell adhesion molecule, Ecadherin, have been postulated to be an early event in the multistep process of tumour metastasis and an important determinant of malignant tumour progression (Birchmeier et al, 1993; Ponta et al, 1995) . E-cadherin is one of a family of functionally related integral membrane glycoproteins responsible for calcium-dependent cell-cell adhesion (Takeichi, 1991) . Human carcinoma cell lines that are negative for E-cadherin expression have been shown to be invasive in two in vitro invasion assay systems (Kinsella et al, 1994a) , and transfection with an E-cadherin cDNA has been shown to suppress the invasive phenotype of human breast and colorectal carcinoma cell lines Kinsella et al, 1994a) . Moreover, colorectal tumour cells deprived of their Ecadherin function by the addition of anti-E-cadherin antibody become invasive in the collagen gel assay and adopt a more singlecell morphology on plastic (Kinsella et al, 1994a) . Reduced Ecadherin expression has been shown to correlate with advanced disease in carcinomas of the breast (Oka et al, 1993) , prostate (Umbas et al, 1992) and bladder (Bringuier et al, 1993) , but the correlation is weaker for carcinoma of the colon Gagliardi et al, 1995) , gastric carcinoma (Mayer et al, 1993) and SCCHN (Schipper et al, 1991; Bowie et al, 1993; Mattjssen et al, 1993; Kinsella et al, 1994b) .
Recently the cytoplasmic carboxy terminus of the E-cadherin molecule has been shown to be linked to the actin cytoskeleton via a-and fB-catenin (McCrea et al, 1991; Ozawa and Kemler, 1992; Knudsen et al, 1995) . The catenins are essential for E-cadherin function (Shimoyama et al, 1992; Oyama et al, 1994; Kawanishi et al, 1995) . E-cadherin is directly associated with 1-catenin via the internal Armadillo-like repeat region of the 1-catenin molecule and is indirectly linked via the a-catenin/,-catenin heterodimeric complex to a-catenin (Alberle et al, 1994; Oyama et al, 1994; Stappert and Kemler, 1994) . E-cadherin also competes with the product of the colonic tumour-suppressor gene, APC (adenomatous polyposis coli), to bind to the internal Armadillo-like repeats of ,B-catenin (Rubinfeld et al, 1993; Su et al, 1993; Hulsken et al, 1994) , while a-catenin links the E-cadherin-catenin complex to a-actinin and the actin cytoskeleton (Knudsen et al, 1995) . Furthermore, it has been suggested that immunohistochemical analysis of changes in a-catenin expression in gastric carcinomas might be a better indicator of the propensity of tumours to metastasize than E-cadherin (Matsui et al, 1994) . a-Catenin downregulation has also been reported to be responsible for a more invasive phenotype in colon tumour cells (Vermeulen et al, 1995) , while re-expression of a-catenin has been reported to suppress tumorgenicity in prostate cells (Ewing et al, 1995) .
In the present study, we have examined 51 samples from 36 patients with SCCHN for expression of E-cadherin and a-and Pcatenin using immunohistochemical techniques and correlated this with the expression of a putative marker of epithelial cell differentiation, involucrin (Hudson et al, 1992 (Hermanek and Sobin, 1992 ) and the performance status was classified using the ECOG scale (Zubrod et al, 1960) . The degree of differentiation of the carcinomas was independently assessed by a pathologist, based on the extent of keratinization and nuclear pleomorphism in haematoxylin and eosin-stained sections taken in parallel to those used for immunohistochemistry.
Antibodies used and their specificities E-cadherin was detected using the human epithelial cadherin-1 (HECD-1) mouse monoclonal IgG (British Biotechnology, Abingdon, UK) against the 150-kDa carboxy-terminal fragment to human E-cadherin. Both a-and ,-catenin were detected using anti-a-and anti-p-catenin mouse monoclonal IgG (Affinity Research, Mamhead Castle, UK). The a-catenin was raised against the 19.4-kDa C-terminal fragment, while the P-catenin was raised against the 23-kDa C-terminal fragment. Involucrin was detected using the human involucrin mouse IgG against the 102-kDa fragment (Sigma Aldrich). The immunolabelling by all the antibodies was performed using the streptavidin-biotin complex method, using the streptavidin ABC kit (Dako, High Wycombe, UK). The optimal dilutions for the antibodies were established in preliminary experiments.
Immunolabelling protocol
Paraffin sections (4 gm) were cut and dewaxed in xylene for 10 min and then placed in two changes of alcohol (90% and 100%) before immersion in methanol and hydrogen peroxide (3%) for 20 min to block endogenous peroxidases. Normal tap water was then used to wash the sections (5 min) followed by 2-min washes in Tris (hydroxymethyl) methylamine-buffered saline (TBS) (pH 7.6). To enhance E-cadherin and a-and 0-catenin staining in formalin-fixed paraffin-embedded tissues, sections were treated with an antigen-retrieval solution in a microwave oven. This method of antigen unmasking denatures proteins and allows linearized strands to be more fully exposed to the detection method (Norton et al, 1993) . Briefly, the slides were immersed in 0.01 M citrate buffer (made from citric acid and balanced to a pH of 6.0) and heated in a 650-watt microwave on full power for 15 min. The slides were then rinsed in TBS, placed in a Shandon sequensa and non-specific binding was blocked with 100 pl of normal goat serum (Vector, Peterborough, UK) at a dilution of 1:20 for 10 min. One hundred microlitres of antibody were added to each section. HECD-1 was incubated at a dilution of 1:200 at 38°C for 2 h. a-Catenin was incubated at a dilution of 1:20 at 370C
for 2 h and 3-catenin was incubated at a dilution of 1:100 for 1 h at room temperature. After incubation with the primary antibodies, the slides were washed for 5 min using TBS. One hundred microlitres of a biotinylated secondary mouse antibody (Amersham) was then applied at a dilution of 1:200 for 45 min, washed in TBS for 5 min and incubated with 100 pl of 1:200 streptavidin-biotin complex for 30 min. After washing with TBS, visualization was achieved with 100 pl of diaminobenzidine (DAB) at a concentration of 1 mg per 10 ml (Sigma Aldrich).
Colonic epithelium was used as a positive control for the Ecadherin and oc-and ,-catenin staining. This tissue type was chosen because of its high antigenicity for the respective molecules. In addition, when possible, the primary tumour blocks were selected to include normal squamous epithelium, which provided an internal positive control. The antigen-retrieval method was validated in preliminary experiments by immunolabelling of frozen sections of carcinoma without microwave pretreatment. The appearances of the sections were identical to those of the paraffin sections subjected to the antigen-retrieval method, confirming that this technique does not produce spurious positivity in this situation. All sections were assessed by two independent observers.
The pattern of immunolabelling was described as normal for all three adhesion molecules when labelling was exclusively membranous with no cytoplasmic labelling and of similar intensity to adjacent normal epithelium. Abnormal labelling included discontinuous or absent membranous labelling, with or without cytoplasmic labelling. For each antigen, the cases were grouped according to whether 76-100%, 51-75%, 26-50% or 0-25% of cells showed the normal pattern of strong membranous staining.
Double immunolabelling for E-cadherin and involucrin expression
For this procedure, E-cadherin was developed first, followed by involucrin. The immunolabelling procedure for E-cadherin was as described above except that the sections were incubated with antibody overnight at 4°C and a tertiary antibody, swine anti-rabbit (Amersham), was used for 30 min at a dilution of 1:100 to enhance epitope recognition. Antibody binding was amplified using rabbit peroxidase anti-peroxidase (Dako, High Wycombe, UK) and visualization was achieved with DAB. The same sections were then incubated with the antibody to involucrin at a dilution of 1 :100 for 1 h at room temperature. After washing with TBS, biotinylated mouse secondary antibody was applied as described previously. Detection of the epitope was achieved using an avidin-biotin /alkaline phosphatase complex (Dako, High Wycombe) at a dilution of 1:100 for 30 min. After washing, visualization was achieved using fast red. The fast red solution was made by dissolving 5 mg of fast red powder (Merck, Leicestershire, UK) in 5 ml of TBS with the addition of two drops of solutions 1 and 2 from the alkaline phosphatase substrate kit followed by three drops of levamisole (Vector, Peterborough, UK). This solution was placed on the sections for 10 min until the sections became red, after which they were washed in TBS and mounted in aqueous mountant.
Statistical analysis
As the data were not normally distributed, non-parametric methods of analysis were used. The Wilcoxon signed-rank test and ranksum tests were used when comparing cell adhesion parameters. Categorical data were displayed in contingency tables when analysing all adhesion parameters with respect to clinicopathological data and analysed by chi-square. Categorical data were further analysed using the multivariate method of categorical modelling (SAS Institute, 1985) . Survival times were calculated using the lifetable method (Armitage and Berry, 1987) using the Lifereg procedure on the SAS software (SAS Institute, 1985) . Differences in survival were investigated using the log-rank test (Peto et al, 1977) .
RESULTS
Host and tumour details of all 36 patients are shown in Table 1 . There was no significant association between histological grade and host and tumour factors either on univariate or multivariate analysis ( grade of lymph node metastases, however, tended to be poorer than the originating primary (P = 0.0001).
Patterns of expression in normal epithelium
E-cadherin showed membranous labelling in all the cells in the lower half of the normal squamous epithelium. Membranous Pcatenin expression was observed in the lower 30-70% of cells in normal keratinizing squamous carcinomas, while membranous xcatenin expression was absent in the basal layer. All the antibodies showed strong membranous labelling of colonic epithelium.
Patterns of expression in primary carcinomas and nodal metastases E-cadherin
None of the primary carcinomas or nodal metastases showed normal E-cadherin expression in 100% of cells (Table 3 ). The loss of strictly membranous E-cadherin expression was accompanied by the appearance of cytoplasmic expression in 29 out of 33 of the primary carcinomas. In the primary tumour sample shown ( Figure  1 A) , E-cadherin expression was stronger than in the corresponding nodal metastases (P = 0.0008). Membranous expression was generally weaker, and cytoplasmic expression was generally greater in nodal metastases than in the corresponding primary carcinomas (Figure 1 B) . There was no significant difference in the pattern of membranous E-cadherin expression between those tumours with and without nodal metastases (P = 0.2960).
Moreover there was no significant association, using either univariate or multivariate analysis, between host and tumour factors and E-cadherin. No correlation was observed between the proportion of cells showing membranous E-cadherin expression and patient survival (P = 0.3748).
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All tumour samples exhibited aberrant discontinuous a-catenin expression. Figure 4A demonstrates severely reduced membranous expression in the primary sample when compared with Ecadherin and ,B-catenin, while the nodal sample showed no membranous a-catenin expression ( Figure 4B ). There was no difference in the proportion of cells expressing a-catenin between the tumours of patients that did not develop neck node metastases and those that did (P = 0.0581) ( Table 5 ). The expression of both variables was reduced in neck nodal metastases compared with the primary tumour (a-catenin, P = 0.0059; ,B-catenin, P = 0.001)
Immunolabelling and differentiation
On double labelling for E-cadherin and involucrin, E-cadherin expression was membranous and the involucrin expression was cytoplasmic in normal epithelium. A strong correlation between membranous E-cadherin labelling and involucrin expression was observed when selected sections were double labelled for both molecules with co-localization of E-cadherin and involucrin in regions of good differentiation ( Figure 5 ).
For all three adhesion molecules, expression was more intense and more confined to the cell membranes in the better differentiated areas of individual sections. Seventy-three per cent of the nodal samples were poorly differentiated and generally exhibited weaker membranous labelling and increased cytoplasmic labelling for all three molecules than the primary samples.
DISCUSSION
Changes in cell adhesion molecules are accepted to have an important role in facilitating the dissemination of tumour cells from the primary site and the establishment of metastases. The expression of the components of the E-cadherin cell adhesion complex have been studied in a variety of human carcinomas in an attempt to correlate changes with advanced disease state and tumour progression. Studies of E-cadherin expression both in squamous carcinomas (Schipper et al, 1991; Bowie et al, 1993; Mattijssen et al, 1993) and in vitro in tongue carcinoma cell lines (Kinsella et al, 1994b) have failed to provide a clear picture for its role in SCCHN. Recently, it has been observed that E-cadherin function is dependent on the integrity of the cytoplasmic proteins a-and P-catenin (Shimoyama et al, 1992; Kawanishi et al, 1995) and, in gastric carcinomas, immunohistochemical analysis showed not only reduced or heterogenous expression of E-cadherin but also reduced a-catenin expression (Matsui et al, 1994; Ochia et al, 1994) .
The immunohistochemical profile of the expression of Ecadherin, a-and 3-catenin has not been determined previously in SCCHN in relation to metastasis and patient survival. In the present study we have evaluated the expression of these molecules in 51 samples of primary carcinomas and nodal metastases from 36 patients. For 14 patients, there were paired primary tumours and nodal metastases, and 19 nodal metastases samples were examined in total. None of the tumour samples showed normal E-cadherin expression and 88% of the primary carcinomas had fewer than 50% of cells exhibiting strictly membranous E-cadherin expression. Loss of membranous E-cadherin expression was associated with expression of E-cadherin in the cytoplasm. As the molecule has to be present at the cell surface to mediate cell-cell adhesion, one can speculate that the presence of E-cadherin in the cytoplasm, by definition, means that it is non-functional (Gagliardi et al, 1995) . A reduction in the cell-cell adhesive properties of greater than 50% in the majority of tumours is significant as the function of some cell adhesion molecules is not linearly related to cell surface expression (Hoffman and Edelman, 1983) . With respect to a-catenin expression, 86% of the samples that showed less than 50% of cells with membranous staining for E-cadherin also showed less than 50% cells staining for a-catenin. Only three tumours with strong membranous E-cadherin expression had negligible ax-catenin expression. Similarly, only one sample with high E-cadherin expression had low 3-catenin expression. Thus, although loss of expression of a-catenin and P-catenin has previously been reported to be important for E-cadherin functionality, the independent loss of catenin expression is unlikely to be important in SCCHN. However, as only a few well-differentiated carcinomas were studied in this series, and E-cadherin expression is greater in well-differentiated carcinomas, we cannot exclude the possibility that loss of catenin expression may be important in some well-differentiated, metastasizing carcinomas. As a high percentage of samples already have reduced E-cadherin expression irrespective of their nodal status or of the nodal status of the patient, changes in the localization of Ecadherin correlate most strongly with the degree of differentiation of individual cells within a tumour. Differentiation status is a powerful prognostic indicator for SCCHN (Cachin, 1975) ; however, in this study, no correlation was observed between reduced membranous E-cadherin expression and survival. None of the patients who at the time of surgery were free of nodal involvement has progressed to nodal disease irrespective of the pattern of E-cadherin expression in their primary tumour. Loss of membranous E-cadherin expression in pancreatic carcinoma has been reported to correlate with lymph node metastasis, high grade and advanced stage (Pignatelli et al, 1994) , but for SCCHN it is clearly not any better a prognostic indicator than poor differentiation status for SCCHN. In a previous study by Schipper et al (1991) , E-cadherin expression was correlated with differentiation and seven out of eight nodal metastases exhibited a complete loss of E-cadherin expression. Contrary to these findings, in both the present study and an earlier study by Mattijssen (1993) , E-cadherin expression was evident in all lymph node metastases. In this study, E-cadherin expression was observed at reduced levels when compared with their corresponding primary tumours, whereas Mattijssen (1993) found that E-cadherin expression was in the same range in both lymph nodes and their corresponding primary tumours. The discrepancy in the results may lie in the fact that different antibodies were used in the studies. Schipper's group used the monoclonal antibody 6F9 which detects the extracellular domain of the E-cadherin molecule , while HECD-1 was used in this study. HECD-1 detects the intracellular cytoplasmic domain (Takechi et al, 1991) . Investigation of the other molecules of the E-cadherin complex did not provide any significant prognostic advantage over E-cadherin alone. Thus, while changes in the expression of the components of the E-cadherin complex in SCCHN may be important in creating the conditions in which metastasis may occur, these changes do not offer a useful adjunct to current prognostic indicators. These data also serve to emphasize that the significance of changes in the E-cadherin complex may vary from tumour to tumour and that this heterogeneity is greater than that observed in colon cancer (Kinsella et al, , 1996 .
In conclusion, the components of the E-cadherin cell adhesion complex are abnormally expressed in all SCCHN. These changes may be permissive for metastasis but do not appear to determine the likelihood of metastasis and are no better indicators of patient outcome than established markers.
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